UF Health First in U.S. To Implant New, Advanced Deep Brain Stimulation System
A team of University of Florida Health neurosurgeons and neurologists recently became the first in the U.S. to implant a newly FDA-approved, technologically advanced deep brain stimulation system designed to more precisely target motor symptoms of Parkinson’s disease and two other movement disorders.
The team performed the procedure to implant Medtronic’s SenSight™ Directional Lead System in early June, shortly after its approval by the U.S. Food and Drug Administration for use in treating symptoms of Parkinson’s disease, dystonia and essential tremor.
The new SenSight™ system combines two recent advancements: sensing capability that allows physicians to monitor brain signals in real-time and optimize settings for stimulation based on that data, and a “directional lead” that enables steering of electrical current for more precise targeting of stimulation through the electrode.
“Directional leads are not new, but combining steering capability with next-generation brain-sensing capability will enable us to learn more about the brain, optimize DBS therapy and tailor it specifically to the needs of each individual patient in a way that has not been possible before,” said Kelly Foote, M.D., a professor of neurosurgery in the UF College of Medicine’s Lillian S. Wells Department of Neurosurgery and the neurosurgeon who performed the first implant.
Learn more about UF Health First in the U.S. To Implant New, Advanced Deep Brain Stimulation System.